Canine vaccine for protection against ehrlichiosis
AssigneeWyeth
InventorsLiangbiao Hu, Thomas Hess, Yu-Wei Chiang, Hsien-Jue Chu
Life of this patent
Estimating the term…
Abstract
The present invention provides a safe and effective vaccine composition which comprises: an effective immunizing amount of an inactivated Ehrlichia canis bacterin; a pharmacologically acceptable carrier; and an immunogenically stimulating amount of an adjuvant system consisting essentially of an antibody response inducing agent and a cell-mediated immunity response inducing agent. The present invention also provides a method for the prevention or amelioration of canine ehrlichiosis in dogs.
Claims24
A vaccine composition which comprises:
- an effective immunizing amount of an inactivated Ehrlichia canis bacterin, a pharmacologically acceptable carrier, and an immunogenically stimulating amount of an adjuvant system consisting essentially of an antibody response inducing agent and a cell-mediated immunity response inducing agent.
2-23. (canceled)
A method for the prevention or amelioration of canine ehrlichiosis in a dog, which comprises administering to said dog a vaccine composition which comprises an effective immunizing amount of an inactivated Ehrlichia canis bacterin, a pharmacologically acceptable carrier, and an immunogenically stimulating amount of an adjuvant system consisting essentially of an antibody response inducing agent and a cell-mediated immunity response inducing agent.
A method for the induction of clinical canine ehrlichiosis in a test animal which comprises administering to said test animal an effective amount of a challenge stock consisting essentially of peripheral blood mononuclear cells infected with a virulent Ehrlichia canis microorganism.
A challenge stock composition that comprises peripheral blood mononuclear cells infected with a virulent Ehrlichia canis microorganism.
Dependencies are inferred from the claim text.